Business Context and Reporting Period
HeartBeam, Inc. filed this Form 8-K on March 3, 2023, reporting financing agreements entered into on February 28, 2023. The company develops cardiac monitoring technology; this filing concerns a potential equity and convertible debt financing.
Key Financial and Financing Terms
- Common stock facility: HeartBeam agreed to sell up to $5.0 million of common stock to Maverick Capital Partners, LLC at 75% of the average calculated volume-weighted average price during the applicable drawdown pricing period.
- Convertible note facility: HeartBeam agreed to issue up to $5.0 million principal amount of convertible notes bearing interest at 6% annually.
- Initial funding: On March 1, 2023, the company issued a $500,000 convertible note and received $500,000 of gross proceeds before expenses.
- Use of proceeds: General corporate purposes, including working capital.
- Conversion terms: The investor may convert all or part of the notes into common stock at 75% of the average calculated VWAP during the applicable drawdown pricing period.
The filing does not provide revenue, profitability, cash flow, operating margins, total debt, cash balances, or liquidity metrics for the reporting period.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative operating or financial results. The material change disclosed is the establishment of potential $10.0 million aggregate financing capacity, consisting of up to $5.0 million in common stock sales and up to $5.0 million in convertible notes, with $500,000 initially funded under the note facility.
Guidance, Outlook, Risks, and Unusual Items
- The filing provides no formal financial guidance or operating outlook.
- Issuances at a discount to VWAP and conversions at a 25% discount could result in substantial dilution to existing shareholders, depending on the company’s share price and the amount ultimately funded or converted.
- The financing is subject to the terms of the securities purchase agreement and note purchase agreement, including drawdown and conversion mechanics that are not fully described in the filing summary.
- The notes accrue interest at 6% and may increase the company’s obligations if not converted.
- The stock and shares issuable upon conversion are to be offered under a prospectus supplement to the company’s effective Form S-3 shelf registration statement, filed February 2, 2023 and declared effective February 10, 2023.
- The filing does not disclose maturity, repayment, default, or other detailed note provisions in the provided text.
Important Facts for Investors to Verify
- Whether additional drawdowns under either facility occurred after the initial $500,000 note issuance.
- The outstanding principal, accrued interest, conversion activity, and remaining availability under the financing arrangements.
- The actual share issuance prices and resulting dilution from discounted stock sales or note conversions.
- The complete terms of the securities purchase agreement and note purchase agreement filed as Exhibits 10.1 and 10.2.
- HeartBeam’s latest cash balance, cash burn, operating results, and ability to fund operations beyond the reported financing.